Abcam, ab215203, Anti-cleaved N-terminal GSDMD antibody [EPR20829-408]

Size: 20µL / 100µL / 1mL
Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) is a rabbit monoclonal antibody detecting cleaved N-terminal GSDMD in Western Blot . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency - Over 110 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20829-408,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:ab215203 mainly recognizes N-terminal GSDMD and can also detect a faint band of full-length GSDMD.The N-term cleaved Gasdermin-D needs inflammatory caspases in response to canonical and non-canonical inflammasome activators (PubMed: 31548300, PubMed: 27418190, PubMed: 26375259). If need to detect cleavage of GSDMD, please ensure that the samples are treated with inflammation before testing.FURTHER INFORMATION ON SPECIFICITY (Chinese Version) available under the product protocols section. This file includes key technical notes of experience when using this product.

Product details:
Product Specifications
Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in WB in human samples.
Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) specifically detects cleaved N-terminal GSDMD (UniProt ID: P57764; Molecular weight: 53kDa) and is sold in 100 µL and 1 mL selling sizes.
Quality and Validation
Abcam's high quality manufacturing and validation processes ensure Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) has been cited over 114 times in peer reviewed journals and is trusted by the scientific community.
Related Products
Conjugation-ready, carrier free format available for antibody clone EPR20829-408 -
ab255983
Target Information
Cleaved N-terminal GSDMD (Gasdermin D) is an important protein fragment involved in the execution of pyroptosis, an inflammatory form of cell death. The N-terminal fragment, generated by cleavage, creates pores in the cell membrane, leading to cell death and the release of inflammatory cytokines. Abnormal regulation of cleaved N-terminal GSDMD is associated with various diseases, including inflammatory disorders like rheumatoid arthritis and neurodegenerative diseases such as Alzheimer's disease, contributing to sustained inflammation and tissue damage.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cleaved N-terminal GSDMD also known as cleaved Gasdermin D is a protein fragment derived from the gasdermin D (GSDMD) molecule with an approximate molecular weight of 31-32 kDa. GSDMD is predominantly expressed in the cytosol of immune cells. Upon activation inflammasome pathways cause the cleavage of GSDMD into its active N-terminal fragment known as GSDMD-N. This cleavage is a critical event that translocates the cleaved form to the plasma membrane where it mediates its function.
Biological function summary
The N-terminal fragment of cleaved GSDMD executes an important role in pyroptosis a type of programmed cell death. This fragment forms pores in the cell membrane allowing the release of pro-inflammatory cytokines. GSDMD does not act alone; it functions as part of a larger molecular complex often interacting with caspases like Caspase-1 and inflammatory molecules which enhance its role in immune responses. The formation of membrane pores by cleaved gasdermin D signifies its fundamental job in enabling cellular defense mechanisms against infections.
Pathways
Cleaved N-terminal GSDMD participates in both pyroptosis and canonical inflammasome pathways. In the inflammasome pathway inflammasomes activate caspases that subsequently cleave GSDMD therefore linking it to a broad inflammatory response. This pathway involves proteins such as Caspase-1 and interleukin-1? which synergize with GSDMD to drive cytokine release. In addition GSDMD cleavage acts downstream of these interactions directly implementing pyroptotic cell death thereby contributing to the body’s innate immune defense.
Cleaved N-terminal GSDMD is notably linked to inflammatory conditions such as sepsis and inflammatory bowel disease. In sepsis the excessive activation of pyroptosis mediated by cleaved GSDMD leads to widespread inflammation and tissue damage. Cleaved GSDMD is also implicated in inflammatory bowel disease where dysregulation of the associated inflammation pathways causes chronic inflammation. In these conditions GSDMD's interaction with Caspase-1 and IL-1? amplifies the inflammatory responses underlining its potential as a target for therapeutic intervention in managing such diseases.